Vaccination against COVID-19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders.

Kaczmarek, Radoslaw;El Ekiaby, Magdy;Hart, Daniel P;Hermans, Cédric;U.S. National Hemophilia Foundation (NHF);et.al.
(2021) Haemophilia (Print) — Vol. 27, n° 4, p. 515-518 (2021)

Files

2021_Kaczmarek_Haemophilia.pdf
  • Open Access
  • Adobe PDF
  • 330.91 KB
Download

Details

Authors
  • Kaczmarek, Radoslaworcid-logo
    Author
  • El Ekiaby, Magdy
    Author
  • Hart, Daniel P
    Author
  • Hermans, CédricUCLouvain
    Author
  • U.S. National Hemophilia Foundation (NHF)
    Collaborator
Show more
Abstract
While COVID‐19 is far from being eradicated, the first COVID‐19 vaccine has now been approved in the U.K., the European Union, Canada and the United States, and vaccinations have been initiated as of December 8, 2020 in the U.K. Additional vaccines have been licensed in the United States, the U.K. and India. Approvals in other jurisdictions and the arrival of additional effective vaccines are imminent. The success of vaccination campaigns will depend on the number of people effectively vaccinated. The vaccinated population will limit the spread of the SARS‐CoV‐2 virus. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Kaczmarek, R., El Ekiaby, M., Hart, D. P., Hermans, C., Makris, M., Noone, D., O’Mahony, B., Page, D., Peyvandi, F., Pipe, S. W., Sannié, T., Schlenkrich, U., Skinner, M. W., Srivastava, A., Bok, A., & Pierce, G. F. (2021). Vaccination against COVID-19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders. Haemophilia (Print), 27(4), 515-518. https://doi.org/10.1111/hae.14271 (Original work published 2021)